Does low-dose atropine slow myopia progression? Still yes.

A study published in Acta Ophthalmologica investigated the use of low-dose atropine for myopia control in a European pediatric population.

Tell me about the study.

A total of 102 myopic children ranging in age from 5 to 16 were included in the retrospective study. Fifty-two of these children were treated with 0.01% atropine once in the evening for at least 1 year and the others acted as controls. The authors measured the rate of myopia progression in both treated and untreated patients over 12 months.

What did they find?

Low-dose atropine significantly slowed myopia progression. In the treated group, 79% of patients had less than 0.50 D myopic progression over 1 year.

Any adverse events?

Five patients complained of photophobia, although not severe enough to discontinue treatment. No systemic adverse events were reported.

Where can I learn more about myopia management/research/treatments?

The Brien Holden website has a nice myopia calculator, along with other useful information. I've written previously about the DIMS lens, a spectacle lens (still in clinical trials) made by Hoya to help control myopic progression. Finally, here’s one more useful myopia management website.


Could I die from a vitrectomy?

Although it's not likely, it can happen, according to a new report on Medscape. A rare complication called an ocular venous air embolism can occur, it is almost always fatal. (via)


Contact Lens Health Week

August 19-23 is the CDC's annual contact lens health week. Learn more here.

Nate Berkus + Novartis

Interior designer Nate Berkus is teaming up with Novartis to help patients with wet AMD who have vision loss adapt their home to make it more functional. (via)

Are you really into contacts?

You should take a trip to this museum.

Thanks for reading! See you next week!